“…Further clinical trials have been completed, focused on evaluation of the efficacy and safety of GSK239512 in Alzheimer's disease, using a randomized, double-blind, placebo-controlled study and cognitive impairment in schizophrenia. The initial report showed that GSK239512 displayed appropriate tolerability up to a maximum dose of 80 mg/day in patients with Alzheimer's disease, with some preliminary evidence for positive effects on attention and memory with modest effect sizes (Nathan et al, 2013). A larger follow study (over 190 mild/moderate Alzheimer's cases) reported GSK239512, up-titrated over 4 weeks (10-20-40-80 mg) followed by a 12-week maintenance phase, compared with sham controls, although it did not display improvement in working memory and other cognitive outcomes, however, it exhibited improved episodic memory, with a reasonable safety profile (Grove et al, 2014).…”